比克恩丙诺在获得性免疫缺陷综合征治疗中的应用及研究新进展

Application and recent research progress of Bictegravir/Emtricitabine/Tenofovir Alafenamide in the treatment of acquired immunodeficiency syndrome

整合酶链转移抑制剂(INSTI)作为核心药物联合2个逆转录酶抑制剂已成为国际上和我国获得性免疫缺陷综合征(AIDS)指南推荐的一线抗逆转录病毒治疗(ART)方案。比克恩丙诺(B/F/TAF,商品名:Biktarvy^(■))是一种基于INSTI的新型复方单片制剂,越来越多的临床数据表明B/F/TAF在初治和经治人类免疫缺陷病毒1型(HIV-1)感染患者中的疗效不劣于目前基于多替拉韦的ART一线方案,且安全性和耐药屏障较高,患者用药体验也较好。本文旨在综述和分析B/F/TAF的新研究进展,为我国临床医护人员提供参考。

The combination of integrase strand transfer inhibitor(INSTI)and two nucleoside reverse transcriptase inhibitors has become the first-line anti-retroviral therapy recommended by international and Chinese acquired immuno deficiency syndrome(AIDS) guidelines,and INSTI are the core antiviral drugs. Bictegravir/Emtricitabine/Tenofovir Alafenamide(B/F/TAF,Biktarvy^(■))is a new type of INSTI based single tablet regimen. Recently,more and more clinical data show that the efficacy of B/F/TAF is not inferior to Dolutegravir based anti-retroviral therapy regimens not only in treatment-naive adults,but also in human immunodeficiency virus 1(HIV-1)virologically suppressed adults. Furthermore,B/F/TAF is associated with better tolerance,higher drug resistance barrier and fewer bothersome symptoms. The purpose of this paper is to review and analyze some new researches about B/F/TAF,so as to provide references for clinical therapy of AIDS therapy.